For providers
OncoExTra® Tissue Genomic Profiling test

Uncover more variants with the full genomic story

The OncoExTra test helps identify alterations in patients diagnosed with advanced cancers, providing all-encompassing insights that can inform about targeted therapy options, immunotherapy selection, and potential clinical trial eligibility.
Lab technician opening the OncoExTra specimen kit box.
For patients with advanced, metastatic, refractory, relapsed, or recurrent cancer
Test analyzes tumor tissue and matched-normal blood samples
Helps inform therapy selection and potential clinical trial eligibility
Lab technician opening the OncoExTra specimen kit box.
Illuminated multi-color tile graphic on dark background.

Offering a low limit of detection to identify 10.9% more alterations than less sensitive tests, OncoExTra may help patients qualify for an FDA-approved matched therapy1

Insights that instill confidence with every decision

There are actionable variants that could be missed by fixed-panel tests. The OncoExTra test utilizes whole-exome and whole-transcriptome sequencing across nearly 20,000 genes to deliver more answers for your patient’s most urgent questions.2,*
All-encompassing genomic profiling
By interrogating DNA and RNA, the OncoExTra test provides ultra-comprehensive genomic profiling that detects clinically actionable variants, with optional IHC stains and tumor-specific panels available to add on for even more insight. †
Clinically actionable results
Results are easy-to-interpret and available approximately 14 days from sample receipt. In a clinical utilization study, 92% of OncoExTra test reports showed ≥1 clinically actionable variant.1,*,†
Patient-matched tumor-normal sequencing
Utilizing patient-matched tumor-normal sequencing, the OncoExTra test provides a gold standard for tumor mutational burden (TMB) calculation and allows for differentiation between germline and somatic variants.2, 3
A gloved lab technician swabbing a sample in a tray.

Refine therapy selection based on germline subtraction

Patient-matched tumor-normal sequencing is considered a gold standard of germline subtraction3 and is an integrated part of every OncoExTra test, so you and your patient can:

  • Limit false positives2
  • Identify the actionable somatic variants2
  • Reduce the overestimation of tumor mutational burden (TMB)3

Turn unknowns into answers with the OncoExTra test

Provider sitting at his desk looking at tablet in his hands with a monitor off to the side.

Calculate what’s covered from the start

The OncoExTra test is covered by Medicare Fee for Service (FFS) for patients meeting coverage criteria. Patients who meet clinical criteria for coverage have zero financial responsibility.
96%
of patients who receive the OncoExTra test have $0
in out-of-pocket costs‡
97%
of patients who have a financial responsibility pay <$100‡

Simple ordering and result tracking. All in one hub.

Quickly place and manage test orders, track results, and access easy-to-interpret reports on the Exact Sciences Provider Hub.
Provider sitting at her desk, working on a laptop.
oncoExtra and Oncodectect logos.

There’s power in pairing

Get a more complete picture of your patient’s advanced solid tumor by pairing the OncoExTra comprehensive genomic profiling (CGP) test with the Oncodetect® molecular residual disease (MRD) test. Together, they provide actionable insights that enable personalized advanced cancer care.

Have questions?

Call us at 1 866-662-6897.